Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/4/?d=1Neue Studien: Europe PMCdePerceptions and Experiences of Patients Across All Skin Tones Living with Psoriasis in Canada.https://www.psoriasis-news.de/articles.html/1_articles/perceptions-and-experiences-of-patients-across-all-skin-tones-living-with-psoriasis-in-canada-r584/IntroductionPsoriasis is a chronic inflammatory skin disease that significantly impacts patients' quality of life. Patients with skin of colour (SoC) often face unique barriers related to gaining access to care, diagnosis and treatment, which can contribute to health disparities. The aim of this study was to assess patient-reported experiences across the psoriasis care continuum in Canada, comparing white and non-white populations.

Methods

A 15-min online survey was administered between 9 December and 19 December 2022 to patients ≥ 18 years with a confirmed psoriasis diagnosis. The survey included 33 questions covering demographics, medical history, psoriasis experience and access to information. Responses were analysed using t-tests at a 90% confidence level to identify significant differences based on ethnicity, treatment users, gender, psoriasis severity and region.

Results

Of approximately 2500 invited participants, 103 met the eligibility criteria: 62 self-identified as white and 41 as non-white. A higher proportion of non-white patients reported severe psoriasis, delays in diagnosis and greater emotional and social burden during the pre-diagnosis stage. Non-white patients were more frequently diagnosed and treated by dermatologists and more commonly used non-topical therapies. Misdiagnosis, often as eczema or dermatitis, was more prevalent among non-white patients. Treatment initiation was more commonly delayed in non-white patients, with 71% reporting difficulty accessing effective therapy, compared to 31% of white patients. A greater proportion of non-white respondents sought additional support and education, especially for mental wellness and advocacy resources.

Conclusion

Disparities in psoriasis care are evident across the experience of patients with psoriasis. Among those who participated in the survey, a greater proportion of the non-white patients faced delayed diagnosis, misdiagnosis, and greater barriers to treatment access, often reflecting more severe disease and unmet informational needs. These findings highlight the importance of culturally competent care and inclusive research to ensure equitable outcomes for all patients with psoriasis. Enhanced representation in clinical trials and targeted health interventions are essential to address these disparities.

Weiterlesen

]]>584Sat, 11 Apr 2026 17:37:02 +0000Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/baseline-th17tc17-and-lag-3-levels-serve-as-candidate-exploratory-markers-for-early-ixekizumab-response-in-psoriasis-r583/No abstract supplied.

Weiterlesen

]]>583Sat, 11 Apr 2026 17:37:02 +0000The Impact of Targeted Therapies on the Bone-Vascular Axis in Psoriasis: A Narrative Review.https://www.psoriasis-news.de/articles.html/1_articles/the-impact-of-targeted-therapies-on-the-bone-vascular-axis-in-psoriasis-a-narrative-review-r576/Weiterlesen

]]>576Fri, 10 Apr 2026 10:21:30 +0000Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/comparative-study-assessing-multiple-switches-between-biosimilar-abp%C2%A0501-adalimumab-atto-and-adalimumab-reference-product-in-patients-with-plaque-psoriasis-r575/IntroductionABP 501, now approved as AMJEVITA® (adalimumab-atto, USA)/AMGEVITA® (adalimumab, EU), is a biosimilar to adalimumab reference product (RP, Humira®) indicated for the treatment of various chronic inflammatory conditions. This multicenter, randomized, double-blind study aimed to investigate the impact of multiple switches between adalimumab RP and ABP 501 as compared with continued-use of adalimumab RP.

Methods

This study (NCT05073315) consisted of a 12-week lead-in period where adults with moderate-to-severe plaque psoriasis received adalimumab RP subcutaneously every 2 weeks (Q2W), followed by a double-blind, two-parallel arm period in which patients were randomized to either the continued-use group (adalimumab RP Q2W, weeks 12-28) or switching group (ABP 501, weeks 12 and 14; adalimumab RP, weeks 16 and 18; ABP 501 Q2W, weeks 20-28). The primary pharmacokinetic (PK) endpoints were area under the serum concentration-time curve (AUCtau) and maximum observed serum concentration (Cmax) between weeks 28 and 30. Secondary endpoints included additional PK assessments and measures of safety, immunogenicity, and efficacy.

Results

A total of 425 patients were enrolled across 85 centers. Adherence to dosing protocol and completion/discontinuation rates were similar between groups. The ratio of geometric least squares means (90% confidence interval; CI) between the continued-use group and switching group for AUCtau was 1.0516 (0.9010, 1.2273) and for Cmax was 1.0044 (0.8717, 1.1574); 90% CIs were contained within the prespecified similarity margin (0.8, 1.25). Secondary endpoints were comparable between groups. There were no new or concerning safety signals.

Conclusion

This study demonstrates PK similarity in patients with plaque psoriasis who underwent three treatment switches between adalimumab RP and ABP 501 as compared with those who received continuous treatment with adalimumab RP. Safety, immunogenicity, and efficacy profiles were comparable. Overall, results support the interchangeability designation of ABP 501 with adalimumab RP, consistent with the US Food and Drug Administration (2019) guidelines.

Trial registration

This study was registered as NCT05073315.

Weiterlesen

]]>575Fri, 10 Apr 2026 10:21:30 +0000Albendazole-loaded chitosan nanoparticle conjugated with hyaluronic acid for the treatment of psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/albendazole-loaded-chitosan-nanoparticle-conjugated-with-hyaluronic-acid-for-the-treatment-of-psoriasis-r574/ObjectiveTo design and develop hyaluronic acid (HA) conjugated Albendazole (ABZ) loaded chitosan nanoparticles (HA-ABZ-CSNP) loaded hydrogel for the treatment of psoriasis.

Significance

Albendazole (ABZ), a commonly used anti-parasitic drug, has garnered a lot of attention lately including anticancer and anti-psoriasis properties. Chitosan nanoparticle followed by conjugation with HA was formulated in hydrogel base making it an excellent strategy for targeting overexpressed CD44 receptor on psoriatic skin as well as alleviating the problems, such as dryness, itchiness associated with psoriasis.

Methods

ABZ-CSNP was formulated by ionic gelation technique followed by conjugation with hyaluronic acid (HA) and was evaluated for particle size, zeta potential, entrapment efficiency, respectively. Developed HA-ABZ-CSNP were incorporated into hydrogel base and were evaluated for in-vitro drug release. Ex-vivo studies were performed. In-vivo studies were performed on Balb/c mice and tests, such as Psoriasis Area Severity Index (PASI), Spleen weight assessment, and histopathological studies were conducted.

Results

Optimized HA-ABZ-CSNP showed a particle size of 170.1 ± 76.38 nm, zeta potential of 31.6 mV, and entrapment efficiency of 98.89%, respectively. Developed HA-ABZ-CSNP hydrogel showed a Korsemeyer and Peppas release model and an in-vitro release of 93.90 ± 32.50 % in around 24 h. Ex-vivo studies were conducted which showed 30.74 ± 13.65% in 24 h. In-vivo studies conducted on Balb/c mice showed reduced PASI, Spleen weight as well as reduced keratinocyte proliferation in histopathological studies.

Conclusions

In conclusion, developed novel formulation of ABZ reduced keratinocyte proliferation making it a possible effective strategy in the management of psoriasis.

Weiterlesen

]]>574Fri, 10 Apr 2026 10:21:30 +0000Core Differentially Expressed Genes in Psoriasis Lesions: An Integrated Analysis of Four GEO Datasets.https://www.psoriasis-news.de/articles.html/1_articles/core-differentially-expressed-genes-in-psoriasis-lesions-an-integrated-analysis-of-four-geo-datasets-r573/PurposePsoriasis is a chronic inflammatory skin disease characterized by abnormal keratinocyte proliferation and differentiation, affecting approximately 2% of the global population.

Patients and methods

This study explored the role of specific molecular biomarkers in the pathogenesis of psoriasis through integrative bioinformatics analysis, aiming to improve diagnostic precision and uncover therapeutic targets. Four independent transcriptomic datasets (GSE34248, GSE41662, GSE50790, and GSE6710) were analyzed using bioinformatics tools to identify consistently dysregulated genes in psoriatic lesions. Subsequently, we constructed a protein-protein interaction (PPI) network using the STRING database and analyzed key gene modules and hub genes involved in disease pathways.

Results

This integrative approach led to the identification of 32 genes consistently dysregulated across all four datasets. Pathway enrichment highlighted significant involvement in biological processes such as keratinization (p = 1.53 × 10-6) and cornified envelope formation (p = 1.93 × 10-5), which are central to the epidermal alterations observed in psoriasis. Several gene families implicated in skin homeostasis and inflammatory regulation were found to contribute to psoriasis pathogenesis.

Conclusion

These findings underscore the relevance of these core genes and pathways in the molecular landscape of psoriasis and offer potential targets for future functional validation and therapeutic intervention.

Weiterlesen

]]>573Fri, 10 Apr 2026 10:21:30 +0000<![CDATA[Association of <i>PTPN22</i> and <i>NLRP3</i> Gene Polymorphisms with Psoriasis Susceptibility in a Han Chinese Population.]]>https://www.psoriasis-news.de/articles.html/1_articles/association-of-ltigtptpn22ltigt-and-ltigtnlrp3ltigt-gene-polymorphisms-with-psoriasis-susceptibility-in-a-han-chinese-population-r572/ObjectiveTo investigate the associations among protein tyrosine phosphatase (PTPN22), nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) and genetic susceptibility to psoriasis in the Jiujiang population.

Methods

A total of 120 psoriasis patients and 90 healthy controls were enrolled. Polymerase chain reaction-based sequencing was performed to determine the distribution of PTPN22 rs1310182, rs2488457, and NLRP3 rs10754558 genotypes. Logistic regression analysis was conducted to evaluate the associations between the genotypes, alleles, and genetic models of these three loci and psoriasis susceptibility. The associations between these polymorphisms and disease subtypes or severity were also explored.

Results

With respect to the PTPN22 rs2488457 locus, the GG genotype and G allele were identified as risk factors for psoriasis susceptibility (p = 0.026 and p = 0.004, respectively). In the dominant model, carriers of the GG genotype exhibited a significantly higher risk of psoriasis than did those with the GC+CC genotype (p = 0.016). No significant associations were observed between the rs1310182 or rs10754558 polymorphisms and psoriasis susceptibility (p > 0.05). In addition, none of the three loci were significantly correlated with the disease subtype or severity (p > 0.05).

Conclusions

In the Jiujiang population, the GG genotype and G allele of the PTPN22 rs2488457 locus may be key factors influencing psoriasis susceptibility.

Weiterlesen

]]>572Fri, 10 Apr 2026 10:21:30 +0000Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/application-of-trichoscopy-and-novel-non-invasive-imaging-techniques-in-the-diagnosis-and-management-of-patients-with-scalp-psoriasis-r571/Weiterlesen

]]>571Fri, 10 Apr 2026 10:21:30 +0000Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.https://www.psoriasis-news.de/articles.html/1_articles/janus-kinase-inhibitors-for-treatment-of-palmoplantar-pustulosis-generalized-pustular-psoriasis-and-palmoplantar-pustular-psoriasis-a-systematic-review-of-the-literature-r570/IntroductionPalmoplantar pustulosis (PPP) is a chronic, recurrent, inflammatory disease and assumed to be a subtype of psoriasis. Pustular psoriasis (PP) is a chronic inflammatory disease that is further subclassified into various entities with different presentations including generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPPP). Given the central role of the JAK-STAT pathway in cytokine signaling, this systematic review evaluated the effectiveness and safety of Janus kinase inhibitors (JAK-I) in these PP subtypes.

Methods

Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed/Medline, Scopus, Web of Science, and Embase up to November 13, 2025. Eligible studies included assessing JAK-I in PPP, GPP, or PPPP. Exclusion criteria were reviews, articles without full-text, SAPHO syndrome, and animal/in vitro studies. Risk of bias was assessed using the NHLBI quality assessment tool for clinical studies and Murad et al.'s checklist for case reports/series.

Results

Thirty-seven studies were included (29 case reports, 4 case series, and 4 clinical studies), encompassing 157 patients (60.5% female; mean age 46.8 years). Treatments involved tofacitinib, upadacitinib, baricitinib, abrocitinib, and topical ruxolitinib. In PPP, pooled meta-analysis demonstrated a PPPASI-50 response rate of 85.5% (95% CI, 71.3-93.3), with upadacitinib achieving 90.9% (95% CI, 81.7-95.7). Case reports and series showed 88.1% clearance or near-clearance within a mean of 2.5 months. GPP patients (n = 5) achieved rapid clearance or marked improvement within 2-12 weeks. Adverse events (18.7%) were generally mild, most commonly acneiform eruptions, headache, and transient liver enzyme elevations, with no severe events reported.

Conclusion

JAK-I demonstrate high response rates and rapid improvement with manageable safety profiles. However, the current evidence is limited by small sample sizes, short follow-up durations, and reliance on case-based data. They represent a promising therapeutic option and warrant further evaluation in larger controlled studies to establish long-term efficacy and safety.

Weiterlesen

]]>570Fri, 10 Apr 2026 10:21:30 +0000Increased Serum Cold-Inducible RNA-Binding Protein Levels in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/increased-serum-cold-inducible-rna-binding-protein-levels-in-psoriasis-r569/BackgroundPsoriasis is a chronic inflammatory skin disorder typified by well-demarcated erythematous plaques with scales. While considered an immune-driven condition, its underlying molecular triggers remain insufficiently defined. Cold-inducible RNA-binding protein (CIRP), a stress-response protein, has recently been recognized as a damage-associated molecular pattern that can stimulate immune responses.

Objective

This study aimed to explore the potential association between circulating CIRP levels and the clinical as well as histological characteristics of psoriasis.

Methods

Serum CIRP concentrations were analyzed in 67 individuals diagnosed with psoriasis and 20 healthy controls. Relationships between CIRP expression and various clinical and histological indices were also examined.

Results

Patients with psoriasis exhibited significantly elevated serum CIRP levels compared to healthy individuals. Although correlations were observed between CIRP and certain clinical and histological indicators, CIRP levels did not significantly differ based on disease severity (Psoriasis Area and Severity Index score), joint involvement, or nail changes.

Conclusion

Our findings support the notion that CIRP may be involved in the immunopathogenesis of psoriasis and could be considered a prospective target for therapeutic modulation.

Weiterlesen

]]>569Fri, 10 Apr 2026 10:21:30 +0000Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/development-and-validation-of-a-prediction-model-for-primary-non-response-to-il-17a-inhibitors-in-psoriasis-r568/No abstract supplied.

Weiterlesen

]]>568Fri, 10 Apr 2026 10:21:30 +0000TYMP upregulation mediated by the hyperactivated IL-17/NF-κB1 axis promotes psoriasis through enhancing aberrant keratinization and neutrophil-mediated inflammation.https://www.psoriasis-news.de/articles.html/1_articles/tymp-upregulation-mediated-by-the-hyperactivated-il-17nf-%CE%BAb1-axis-promotes-psoriasis-through-enhancing-aberrant-keratinization-and-neutrophil-mediated-inflammation-r567/No abstract supplied.

Weiterlesen

]]>567Fri, 10 Apr 2026 10:21:30 +0000Effects of biologics and small-molecule inhibitors on lipid profiles in patients with psoriasis or psoriatic arthritis: An analysis of current evidence.https://www.psoriasis-news.de/articles.html/1_articles/effects-of-biologics-and-small-molecule-inhibitors-on-lipid-profiles-in-patients-with-psoriasis-or-psoriatic-arthritis-an-analysis-of-current-evidence-r566/Weiterlesen

]]>566Sun, 05 Apr 2026 12:58:53 +0000Assessing the reliability and quality of content on social media regarding biologic therapies for psoriasis: A cross-sectional content analysis.https://www.psoriasis-news.de/articles.html/1_articles/assessing-the-reliability-and-quality-of-content-on-social-media-regarding-biologic-therapies-for-psoriasis-a-cross-sectional-content-analysis-r565/BackgroundBiologic agents are an important novel therapeutic option for moderate-to-severe psoriasis. In recent years, TikTok and Bilibili have gradually become important channels for Chinese patients to obtain health information. This study aims to evaluate the content, quality, reliability, and transparency of videos related to biologic therapy for psoriasis on these platforms.

Methods

We searched both platforms using the dual keywords "psoriasis" and "biological agents," confirmed compliance with relevant criteria, and collected the top 150 videos based on their composite rankings. Fundamental characteristics, uploader categories, and content types were documented. Two independent reviewers evaluated video quality using the mDISCERN, GQS, and the JAMA criteria. Nonparametric tests were performed for group comparisons, and Spearman correlation analysis was applied.

Results

Bilibili videos more frequently addressed medical expenses, types of biologic agents, and recurrence, whereas TikTok videos focused on etiology and clinical manifestations. The video quality was barely acceptable. On TikTok, the median GQS, mDISCERN, and JAMA scores were 3.00 (2.25, 4.00), 3.00 (3.00, 4.00), and 2.00 (2.00, 3.00). On Bilibili, the median scores were 3.00 (2.00, 4.00), 3.00 (2.00, 4.00), and 1.00 (1.00, 3.00). Videos uploaded by professional organizations achieved the highest GQS (median 4.00, IQR: 4.00-4.00) but had the lowest engagement. Engagement metrics showed a moderate correlation with quality scores (P < 0.05).

Conclusions

This study found that videos related to biologic therapy for psoriasis lack content completeness, with overall quality, reliability, and transparency remaining at a suboptimal level. Greater participation by professional organizations and increased visibility of their videos should be encouraged to promote the dissemination of high-quality content. This study provides preliminary insights for health communication strategies and highlights the necessity of strengthening content regulation.

Weiterlesen

]]>565Sun, 05 Apr 2026 10:37:31 +0000Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative.https://www.psoriasis-news.de/articles.html/1_articles/definition-of-the-terms-used-to-describe-psoriatic-disease-datasets-a-hippocrates-initiative-r564/Weiterlesen

]]>564Sun, 05 Apr 2026 10:37:31 +0000Subclinical psoriatic arthritis: concepts, dilemmas, and research needs.https://www.psoriasis-news.de/articles.html/1_articles/subclinical-psoriatic-arthritis-concepts-dilemmas-and-research-needs-r563/Weiterlesen

]]>563Sun, 05 Apr 2026 10:37:31 +0000Psoriatic arthritis-evolution of our understanding of the phenotype.https://www.psoriasis-news.de/articles.html/1_articles/psoriatic-arthritis-evolution-of-our-understanding-of-the-phenotype-r562/Weiterlesen

]]>562Sun, 05 Apr 2026 10:37:31 +0000Human Immunodeficiency Virus-Associated Vasculitis: A Case Report of Sensorineural Hearing Loss, Bell's Palsy, and Psoriasis Guttatahttps://www.psoriasis-news.de/articles.html/1_articles/human-immunodeficiency-virus-associated-vasculitis-a-case-report-of-sensorineural-hearing-loss-bells-palsy-and-psoriasis-guttata-r561/No abstract supplied.

Weiterlesen

]]>561Sun, 05 Apr 2026 10:37:31 +0000A Diagnostic Pitfall: Secondary Syphilis Mimicking Psoriasis in a Patient With Alcoholic Liver Diseasehttps://www.psoriasis-news.de/articles.html/1_articles/a-diagnostic-pitfall-secondary-syphilis-mimicking-psoriasis-in-a-patient-with-alcoholic-liver-disease-r560/No abstract supplied.

Weiterlesen

]]>560Sun, 05 Apr 2026 10:37:31 +0000'I Didn't Know, I Definitely Guessed.' Exploring Pre-Registration Podiatry Students' Approach to Identifying Dermatological Conditions in Different Skin Tones, a Mixed Methods Study.https://www.psoriasis-news.de/articles.html/1_articles/i-didnt-know-i-definitely-guessed-exploring-pre-registration-podiatry-students-approach-to-identifying-dermatological-conditions-in-different-skin-tones-a-mixed-methods-study-r559/BackgroundResearch suggests that healthcare professionals find it more difficult to correctly diagnose dermatological conditions in the nonwhite patient demographic. People of colour experience higher rates of delayed and misdiagnosis, contributing to an increased mortality risk and increased health inequalities that remain widespread throughout the health care setting. This study aimed to investigate podiatry student's ability, confidence, approaches and perceptions in diagnosing dermatology pathologies in different skin tones.

Methods

A mixed methods explanatory sequential design was undertaken with pre-registration podiatry students from universities across South-central England. Participants completed a validated pictorial multiple-choice questionnaire comprising six images of either eczema or psoriasis in three different skin tone categories: light, medium or dark. Results were used to inform focus groups and a process of thematic analysis explored participants perceptions surrounding their diagnostic approaches and underpinning confidence.

Results

The medium skin tone (Fitzpatrick groups III/IV) was associated with the most correct responses for psoriasis (69%) followed by light skin tone (Fitzpatrick groups I/II) with 48%. Psoriasis in darker skin tones (Fitzpatrick groups V/VI) received the least correct responses (3%). In eczema, results were more evenly spread with darker skin tones (Fitzpatrick groups V/VI), receiving a slightly higher percentage of correct diagnoses (39%). Qualitative analysis revealed two emergent themes: (i) reports on confidence and apprehension and (ii) limitations in education provision: each with a series of sub-themes. Participants reported barriers to their diagnostic ability included an underrepresentation of dark skin tones in medical images and inadequate exposure to pathology on patients with dark skin tones.

Conclusions

There was a notable lack of confidence in participants' ability to correctly diagnose dermatological pathology, particularly in dark skin tones. This study addresses the research gap in podiatric health inequalities and pinpoints the associated educational shortcomings from the podiatry education perspective.

Weiterlesen

]]>559Sun, 05 Apr 2026 10:37:31 +0000A phosphorous-based dendrimer targets mitochondria and normalizes the keratinocyte proliferation/differentiation balance to improve psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-phosphorous-based-dendrimer-targets-mitochondria-and-normalizes-the-keratinocyte-proliferationdifferentiation-balance-to-improve-psoriasis-r558/Weiterlesen

]]>558Fri, 03 Apr 2026 18:19:13 +0000Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/systemic-type-i-interferon-blockade-mitigates-insulin-resistance-in-a-preclinical-model-of-psoriasis-r557/Weiterlesen

]]>557Fri, 03 Apr 2026 18:19:13 +0000The protocol for a patient-driven online prospective European observational cohort aiming to determine risk factors for the development of psoriatic arthritis among people living with psoriasis: the HIPPOCRATES Prospective Observational Study.https://www.psoriasis-news.de/articles.html/1_articles/the-protocol-for-a-patient-driven-online-prospective-european-observational-cohort-aiming-to-determine-risk-factors-for-the-development-of-psoriatic-arthritis-among-people-living-with-psoriasis-the-hippocrates-prospective-observational-study-r556/BackgroundUp to one-third of people living with psoriasis develop psoriatic arthritis (PsA), and the majority have active psoriasis prior to the development of arthritis. Clinical risk factors, such as nail involvement, in conjunction with novel blood biomarkers, could improve PsA risk monitoring and early diagnosis.

Objectives

The aim of the HIPPOCRATES Prospective Observational Study (HPOS-www.hpos.study) is to follow a cohort living with psoriasis and identify risk factors for the development of PsA.

Design

HPOS is a patient-driven online prospective European observational cohort.

Methods

Adult participants with psoriasis but with no prior diagnosis of PsA are eligible. Participants are invited to provide consent and join the study online. They complete a semi-structured questionnaire to collect data on demographics, psoriasis, comorbidities, risk factors for PsA, and the Psoriasis Epidemiology Screening Tool screening questionnaire. Follow-up is conducted through a questionnaire every 6 months. The primary outcome is the new onset of PsA confirmed by a diagnosis from their doctor. The study will also collect peripheral blood samples from a subset of participants for biomarker identification.

Ethics

This study follows the principles of the Declaration of Helsinki. To date, ethical approval has been granted by independent ethical committees in 10 countries.

Discussion

Studying a cohort of individuals with psoriasis will allow us to identify risk factors for arthritis development and to develop a risk calculator. This can support focused efforts on screening, patient education, and even studies looking to delay or prevent the onset of arthritis. This study, run via remote online data collection, provides an efficient way to recruit a large cohort (25,000) across multiple countries. However, challenges have had to be addressed with some key changes in study design, ethical review, and recruitment strategies required for each individual country.

Trial registration

HPOS, Clinicaltrials.gov ID: NCT05858528, IRAS number 325080; https://clinicaltrials.gov/study/NCT05858528?locStr=United%20Kingdom&country=United%20Kingdom&cond=Psoriasis&term=HPOS&aggFilters=status%3Anot%20rec&rank=1.

Weiterlesen

]]>556Fri, 03 Apr 2026 18:19:13 +0000Genetic pharmacoepidemiology of JAK inhibitors in chronic immune-mediated skin diseases: implications for precision therapy and medication safetyhttps://www.psoriasis-news.de/articles.html/1_articles/genetic-pharmacoepidemiology-of-jak-inhibitors-in-chronic-immune-mediated-skin-diseases-implications-for-precision-therapy-and-medication-safety-r555/No abstract supplied.

Weiterlesen

]]>555Fri, 03 Apr 2026 18:19:13 +0000The Effects of Periodontal Treatment on Psoriasis: A Systematic Review of Limited Clinical and Preclinical Evidence.https://www.psoriasis-news.de/articles.html/1_articles/the-effects-of-periodontal-treatment-on-psoriasis-a-systematic-review-of-limited-clinical-and-preclinical-evidence-r554/Background/Objectives: Psoriasis and periodontitis share inflammatory pathways. Current evidence suggests a bidirectional non-causal relation. However, the evidence on the effects of periodontal treatment on psoriasis outcomes (severity, inflammatory markers, quality of life) is limited. This study aims to synthetize the available clinical and preclinical evidence of periodontal treatment effects on psoriasis outcomes, in patients with comorbid psoriasis and periodontitis (CRD420261298145). Methods: Several databases (PubMed, WebOfScience, ScienceDirect, ProQuest and GoogleScholar) were searched for relevant articles, without language or time restrictions. We included randomised and non-randomised clinical studies on humans, and controlled animal experiments. Interventions included periodontal treatment (surgical and non-surgical). Outcomes were the Psoriasis Area and Severity Index and dermatology-specific quality of life scores; secondary outcomes included inflammatory biomarkers and periodontal parameters. Studies were screened in duplicate, data extracted independently and risk of bias was assessed using Cochrane RoB 2, ROBINS I, NOS and SYRCLE. Results: A total of five studies were included in this systematic review (four clinical studies and one preclinical studies). Three studies directly assessed post-treatment psoriasis outcomes, with two studies investigating inflammation mediators as secondary outcomes. Two studies directly assessed PASI (Psoriasis Area and Severity Index) modifications, both studies confirming PASI scores decreasing post-periodontal treatment; one study also reported DLQI (Dermatology Life Quality Index). Typical follow-up durations ranged from 8 to 10 weeks for interventional studies, to 5 years for one cohort study. Conclusions: Although momentarily limited by the small number of available studies, the results of this review suggest that periodontal treatment may be associated with improvements in psoriasis outcomes. Further studies on larger samples, with longer follow-up periods would be necessary to confirm and possibly strengthen the existing results.

Weiterlesen

]]>554Fri, 03 Apr 2026 18:19:13 +0000